other material
confidence high
sentiment positive
materiality 0.85
Corbus reports CRB-701 42.9% cORR in 2L OPSCC at 3.6 mg/kg; registrational study planned summer 2026
Corbus Pharmaceuticals Holdings, Inc.
- cORR 42.9% (9/21) in 2L OPSCC at 3.6 mg/kg; median DOR 6.3 mo, PFS 5.6 mo.
- cORR 34.4% (11/32) in 2L cervical cancer at 3.6 mg/kg; 2 complete responses, DOR 8.0 mo.
- Safety: treatment discontinuations 2.8%; no Grade 5 events; ocular AEs manageable.
- FDA alignment on registrational trials: TEMPO-1 (OPSCC, n=250) to start summer 2026.
- 85.4% of OPSCC patients HPV+; 8 of 9 responders in OPSCC were HPV+.